(OSE) – Globe Newswire
-
OSE Immunotherapeutics Appoints Alexis Vandier as Chief Executive Officer
-
OSE Immunotherapeutics Reports on its 2022 Combined General Shareholder’s Meeting
-
OSE Immunotherapeutics Announces Collaboration with Microsoft
-
OSE Immunotherapeutics Appoints its International Scientific Advisory Board
-
Four Poster Presentations at 2022 ASCO Annual Meeting
-
OSE Immunotherapeutics Announces Four Poster Presentations of Neoepitope Combination Tedopi® in Immuno-Oncology at ASCO 2022
-
OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression
-
OSE Immunotherapeutics To Present at ‘Immuno-Oncology Summit Europe’ and at ‘Tumor Myeloid-Directed Therapies Summit’ In London and Boston
-
Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncolog
-
OSE Immunotherapeutics Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy
-
OSE Immunotherapeutics Invited to Present Preclinical Data on its PD-1/IL-7 Bifunctional Program BiCKI®-IL-7 Cancer Immunotherapy
-
OSE Immunotherapeutics Reports 2021 Financial Results: Major Progress on its Clinical Programs and a Solid Cash Position to Support its Activities
-
OSE Immunotherapeutics Receives First Notice of Allowance for a US Patent Covering Anti-PD1 Monoclonal Antibody OSE-279 And its Use in Cancer Treatment
-
OSE Immunotherapeutics Provides Positive Long Term Memory Responses with CoVepiT, its T Lymphocyte Multi-Target Anti-COVID Vaccine
-
Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses from the Phase 1 Clinical Trial with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors
-
OSE Immunotherapeutics Announces Appointment of Alexandre Lebeaut as an Independent Member of the Board of Directors
-
OSE Immunotherapeutics is Pleased to Announce that Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, has Obtained FDA Fast-Track Designation for CD28 Antagonist VEL-101/FR104
-
Transfer of OSE Immunotherapeutics’ Shares from Compartment C to Compartment B of Euronext Paris from January 31, 2022
-
OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, for CD28 Antagonist VEL-101
-
OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients
-
OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles
-
OSE Immunotherapeutics Strengthens Leadership Team with the Appointment of Laurence de Schoulepnikoff as Chief Business Officer
-
OSE Immunotherapeutics is Pleased to Announce the Continuation of its Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011 in Ulcerative Colitis after the Interim Futility Analysis
-
OSE Immunotherapeutics Presents First Preclinical Efficacy Data on Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia
-
OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical Development of CoVepiT, its Multi-Target T-cell Anti-COVID Vaccine
-
OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer
-
OSE Immunotherapeutics Presented New Translational Data on Tedopi® and Preclinical Data on PD-1/IL-7 Bifunctional Program BiCKI®-IL-7
-
OSE Immunotherapeutics Presented the First Positive Preclinical Efficacy Data on CLEC-1, a Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy
-
OSE Immunotherapeutics to Present New Preclinical Data at Upcoming Bispecific Antibody and Immunology Conferences
-
OSE Immunotherapeutics to Present New Clinical and Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
-
OSE Immunotherapeutics to Host Today a Virtual “Immuno-Oncology R&D Day”
-
OSE Immunotherapeutics Receives New European Patent Notice of Allowance for Tedopi®
-
Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in combination with anti-PD-1 Antibody Ezaben
-
OSE Immunotherapeutics to Host an “Immuno-Oncology R&D Day” On October 12th, 2021
-
OSE Immunotherapeutics Announces H1 2021 Results and Provides a Corporate Update
-
OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial in Secondary Resistant Non-Small Cell Lung Cancer Patients at the European Society for Medical Oncology (ESMO
-
OSE Immunotherapeutics To Present Positive Results of Tedopi® Phase 3 Clinical Trial in Non-Small Cell Lung Cancer Patients in Secondary Resistance to Immune Checkpoint Inhibitors At the European Soc
-
Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021
-
Boehringer Ingelheim and OSE Immunotherapeutics to Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021
-
OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Tedopi®
-
OSE Immunotherapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
-
OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer
-
Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome
-
OSE Immunotherapeutics Announces Upcoming Investor Conferences and R&D Day
-
OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study
-
OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank
-
OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT, OSE’s Multi-Target Second-Generation COVID-19 Vaccine
-
OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting
-
OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer
-
OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine
Back to OSE Stock Lookup
